Follow genetic findings back to the exact experiments and reported results behind them.Know what the science actually supports before you trust the answer.
Press Enter β΅ to search claims
Explore by Goal
"Biology gives you a brain. Life turns it into a mind."
- Jeffrey Eugenides
Quick Explanation
Copied
What the best evidence really supports
The core study supports a temporal association between (i) nuclear deacetylation activity, (ii) loss of acetylated histone H4 (AcH4) at neuronal promoters, and (iii) apoptosis-linked gene silencing after optic nerve crush (ONC), with HDAC inhibition (TSA) partially preserving promoter accessibility/expression (e.g., Fem1c reporter) and reducing cell loss.
Key caution: promoter AcH4 deacetylation is shown for a limited gene set and causality is inferred (strongly), not fully proven genome-wide in RGCs.
Primary evidence:
Long Explanation
Battle-test: βAcH4 promoter deacetylation predicts gene silencing during apoptosisβ
Date: Apr 01, 2026 β’ Evidence is restricted to the provided raw-study extracts.
1) Visual evidence of the temporal chain (ONC model)
From the provided study extract: nuclear HDAC activity rises; AcH4 in GCL falls; both track apoptotic progression timepoints.
Numbers used for plot: the extract states ~50% rise at day 5 (P=0.0014) and continued elevation at day 7 (P=0.0006), but does not provide an exact numeric % for day 3 or an exact % for day 7.
Source:
2) Direct AcH4 loss in the ganglion cell layer (GCL)
Extracted numeric point: AcH4 ~45% of control by day 5; partial recovery below control at day 7.
The extract provides the strongest numeric anchor: day 5 β 45% of control (P<0.0001 for days 1,3,5 vs control) and day 7 partially recovered but still below control (P=0.04). Day 3 numeric % is not specified.
Source:
3) βPredicts silencingβ β what is actually measured
HDAC activity assay (nuclear fraction) shows increased deacetylation capacity after ONC and is fully inhibited by TSA in the assay fraction.
AcH4 immunostaining shows decreased AcH4 signal in GCL following ONC.
ChIP-qPCR for AcH4 at selected promoters shows early promoter deacetylation at a predefined downregulated gene panel; upregulated genes show different (often later) acetylation dynamics.
TSA functional readouts show partial preservation of a promoter-driven reporter (Fem1c Rosa3/R3 Ξ²-Geo) and reduced RGC loss.
This supports a mechanistically consistent temporal model, but βpredictsβ can be read as causality or strong statistical predictionβthose are not fully established in the extract.
Directionality is taken from the extract: downregulated genes (Thy1, Brn3b, Nrn1, Fem1c, BclX) show promoter H4 acetylation decreases early (including day 1 and persistent at day 3), while upregulated genes (notably Bim) show increased promoter acetylation by day 3 and elevated by day 5; cJun shows a day-1 decrease that is not significant and later changes.
Source:
4) Causality test proxy: TSA preserves promoter-driven expression and reduces cell loss
Extracted from reporter and Nissl cell-loss analyses.
Extracted cell loss values: crush ~36.4% (SE 3.4), crush+DMSO ~31.2% (SE 2.9), crush+TSA ~14.4% (SE 5.3), with P=0.005 vs crush and P=0.01 vs DMSO.
Source:
5) Strength of evidence for the claim βAcH4 promoter deacetylation predicts silencingβ
Supportive (what is well-aligned)
Temporal ordering: nuclear HDAC activity and HDAC3 nuclear localization align with loss of AcH4 and apoptotic progression markers.
Direct promoter-level chromatin readout: ChIP detects promoter AcH4 decreases for downregulated genes and differential dynamics for upregulated genes within an early apoptosis time course.
Functional intervention consistency: TSA (HDAC inhibitor) blocks nuclear HDAC activity and partially preserves a promoter-driven reporter and reduces cell loss.
Critical gaps / failure modes (where βpredictsβ may overreach)
Causality is not fully proven genome-wide in RGCs: the strongest claim in the extract is consistent with causality, but the evidence set covers a limited gene panel rather than a genome-wide promoterβexpression predictive model.
Bulk retina dilution risk: HDAC activity and transcript analyses may dilute RGC-specific signals; RGC-enriched analyses are not stated as consistently performed across all assays.
TSA is not isoform-specific: broad HDAC inhibition can have off-target effects and cannot cleanly separate HDAC2 vs HDAC3 contributions in the entire chromatin landscape.
βPredictionβ vs βassociationβ: the extract provides time-course coherence, but does not provide a statistical predictive model (e.g., cross-validated promoter AcH4 β gene silencing across many genes).
6) Epistemic humility: what would most disprove the claim?
Disproof would look like:
HDAC inhibition (or HDAC3-specific perturbation) fails to preserve promoter AcH4 and reporter expression despite apoptosis markers progressing.
AcH4 promoter loss occurs but gene silencing does not follow for the same targets (dissociation between AcH4 and transcriptional repression).
Genome-wide analysis finds no enrichment of promoter AcH4 dynamics among silenced genes (gene-panel specificity would be falsified).
These are not falsified by the provided extract; they are the main remaining uncertainties implied by its scope.
7) βMechanistic plausibilityβ anchor (context from broader chromatin silencing literature)
The idea that neuron-gene repression uses HDAC recruitment is consistent with prior mechanistic chromatin-repression studies, supporting that deacetylation can drive transcriptional silencing.
(Note: this does not prove the ONC-specific causal chain; it supports biological plausibility.)
8) Practical next: targeted tests that sharpen βpredictionβ
RGC-enriched ChIP + RNA for a much larger promoter set across the same ONC time course (then test whether promoter AcH4 changes predict repression by effect size and cross-validation).
HDAC3-specific perturbation (genetic, not broad pharmacology) to isolate the HDAC3βAcH4βsilencing step.
Temporal separation: experimentally delay/de-couple AcH4 loss from apoptosis progression markers to test directionality.
All key quantitative claims above are drawn from the provided extract for 10.1186/1471-2202-11-62; any plotted values not explicitly numeric in the extract are shown as directional approximations (clearly labeled in-axis and described in text).
It extracts the provided time-point anchors into a promoterβsilencing timeline figure, then computes directional consistency scores between HDAC activity, AcH4, and apoptosis-stage markers for the ONC model.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
AcH4 promoter loss is a byproduct of apoptosis without functional impact on silencing; TSA would then fail to preserve reporter expression and promoter AcH4βcontradicted directionally by the Fem1c reporter rescue and RGC loss reduction.
HDAC1/HDAC2 changes alone explain silencing independently of HDAC3 nuclear translocation; the extract instead emphasizes HDAC3 translocation co-localizing with apoptosis progression and AcH4 loss, arguing against a purely HDAC1/2-centric model in this context.
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion